Encorafenib is a targeted therapy used for cancers with BRAF gene mutations. Information regarding its price, clinical efficacy, and preparation for medication is of significant reference value for patients' treatment decisions. This article details the latest market price of Encorafenib in 2026, its therapeutic characteristics, and necessary preparations before use, providing a comprehensive guide for patients.
Latest Price of Encorafenib per Box in 2026
Generic Version (BigBear Pharma, Laos)
In 2026, the international market price for the BigBear version of Encorafenib is approximately $689 USD per box.
Factors Influencing Price
The final retail price is affected by multiple factors, including procurement channels, shipping conditions, and tariff policies. Prices for the same product may fluctuate reasonably across different regions.
Purchasing Advice
Patients should select the appropriate drug specifications based on their treatment regimen and make purchasing decisions under the guidance of professional medical personnel.
Efficacy of Encorafenib
Encorafenib has demonstrated significant clinical results in treating cancers with specific genetic mutations. Understanding these characteristics helps guide treatment expectations.
Melanoma Treatment
For patients with BRAF V600E/K mutation-positive melanoma, the combination of Encorafenib and Binimetinib has shown prolonged median progression-free survival (PFS) and a high objective response rate (ORR).
Colorectal Cancer (CRC) Treatment
For BRAF V600E mutant metastatic colorectal cancer, the combination of Encorafenib and Cetuximab significantly extends median overall survival (OS) compared to traditional chemotherapy.
Non-Small Cell Lung Cancer (NSCLC)
In patients with BRAF V600E mutant NSCLC, combination therapy involving Encorafenib achieves a high overall response rate and prolonged median duration of response (DOR).
